You are here: Home » PTI Stories » National » News
Business Standard

Sanofi Launches 'Once Daily' Oral, Teriflunomide 14 mg Tablet 'Aubagio'- for Treatment of Multiple Sclerosis in India

Press Trust of India  |  MUMBAI 

/ -- - (Teriflunomide, 14 mg) offers patients diagnosed with the efficacy and convenience of once-a-day oral treatment

- Over 200,000 people in are living with Multiple Sclerosis[1]


Genzyme, the specialty care global business unit of Sanofi, brings to - (Teriflunomide, 14 mg), from its international (MS) portfolio. is a chronic debilitating of the nervous system with varied symptoms like weakness in the limbs, poor vision, or slurred speech.

(Logo: https://mma.prnewswire.com/media/793372/Sanofi_Genzyme_Logo.jpg )

(Photo: https://mma.prnewswire.com/media/793371/Aubagio_Teriflunomide_14_mg.jpg )

(Teriflunomide, 14 mg) is the first original 'once-daily' oral 'modifying therapy' (DMT) for Multiple Sclerosis to be approved in It offers an effective, safe and a convenient option that is indicated as a first-line treatment for relapsing forms of Multiple Sclerosis that must be taken once a day, with or without

Commenting on the launch, N. Rajaram, Managing Director, India, said, "There are around two lakh people living with this in India. There are increasing numbers of cases being detected due to greater awareness and access to better diagnostic facilities. Millions of patients depend on us for their needs, and as a health journey partner, we understand the many challenges that people with Multiple Sclerosis face."

He added, "For over a decade has invested in developing and delivering novel for around the world; and with that, we have now brought our original to India. This product has the potential to offer an efficacious and convenient treatment regimen of just once a day oral tablet, vis--vis common treatment options that are injectables. With Aubagio (Teriflunomide, 14 mg), we reiterate Sanofi Genzyme's commitment to improve and empower the lives of people with debilitating in India."

Dr. Shalini Menon, Head - Medical Affairs, India & South Asia, Sanofi, said, "Aubagio (Teriflunomide, 14 mg) is a differentiated disease modifying therapy, that blocks the enzyme involved in multiplication of overactive immune cells. When taken daily, Aubagio (Teriflunomide, 14 mg) reduces the number of overactive immune cells that cause the disease flare-ups, while still allowing normal immune cell activity to occur. It is important to note that Aubagio (Teriflunomide, 14 mg) has demonstrated consistent efficacy in reducing the frequency of relapses, delaying the accumulation of physical disability and, arresting further decrease in brain volume. In addition, given its convenience as an oral medicine, Aubagio (Teriflunomide, 14 mg) encourages people with Multiple Sclerosis to continue with long-term treatment."

First approved by the US in 2012, Aubagio (Teriflunomide, 14 mg) has a strong global presence today with approvals in more than 81 countries.[3]It has been extensively studied in more than 5,500 patients with up to 13 years of clinical and follow-up studies with proven clinical efficacy, safety and tolerability outcomes.[3] Globally, more than 85,000 patients with Multiple Sclerosis are benefitting from the use of Aubagio [3].

About Multiple Sclerosis:

Multiple Sclerosis is an autoimmune, of the nervous system that affects the spinal cord and brain. In Multiple Sclerosis, there is progressive damage to the sheath that protects nerve cells, impairing communication between the brain and the nervous system. Signs and symptoms vary from one person to another and may include: weakness and in the limbs, poor vision, tingling and in parts of the body, unsteady gait, lack of coordination, or slurred speech. Most people develop a 'relapsing-remitting' form of Multiple Sclerosis where symptoms ('relapses') may last for days or weeks and then improve completely or partially. This is then followed by a period of remission that could last for months or even years.[2]Multiple Sclerosis is a common cause of disability that usually affects young persons during their most productive years but only 45% of all patients are correctly diagnosed.[4] Research shows across the world, over 2.3 million people are living with Multiple Sclerosis.[5]

About Aubagio (Teriflunomide, 14 mg)

Aubagio (Teriflunomide, 14 mg) is an innovator product with almost 13 years of proven clinical efficacy, safety and tolerability data, and is a best in class medication for relapsing and remitting Multiple Sclerosis. It is a differentiated Disease-Modifying Therapy (DMT), which works by blocking the enzyme needed for immune cells to keep multiplying at an overactive rate. When taken daily, Aubagio reduces the number of overactive immune cells [that causes the disease flare-ups, while still allowing normal immune cell activity to occur]. Unlike other medicines, Aubagio is India's first innovator 'once-daily' oral pill to treat Multiple Sclerosis in India. It can be taken any time of the day, with or without This ensures patient adherence and convenience, both of which are missing in therapies.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global company focused on human health. We prevent with vaccines, provide innovative treatments to fight and ease suffering. We stand by the few who suffer from and the millions with With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into solutions around the globe.

Sanofi Genzyme, the specialty care global business unit of Sanofi, is focused on rare diseases, multiple sclerosis, and immunology. It focuses on developing specialty treatments for debilitating that are often difficult to diagnose and treat, providing hope to patients and their families. Sanofi is recognized as one of the industry's most generous in-kind givers and 2018 marks the 20th year of Sanofi Genzyme's charitable access program in India. Through this program, known as INCAP (INdia Charitable Access Program), Sanofi is currently providing free to patients with (LSDs) in India.

[1] http://www.mssocietyindia.org/: Accessed on July 4, 2018 (This was in the context of - Currently, in almost 90% cases , is driven by injectables)

[2] Multiple Sclerosis. Available at: https://on May 24, 2018.

[3] data on File

[4] Genzyme data on File (As per market research done in 2015)

[5]

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, December 05 2018. 10:30 IST
RECOMMENDED FOR YOU